Evidence map›Paper›PMID 40089661›Full record

ArticleBMC cancer2025

Lung Cancer Biomarker Database (LCBD): a comprehensive and curated repository of lung cancer biomarkers.

Yinghong Li, Zhuohao Tong, Yinqi Yang, Yu Wang, Lu Wen, Yuke Li, Mingze Bai, Yongfang Xie, Bo Li, Kunxian Shu

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in BMC cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Yinghong Li *Chongqing Key Laboratory of Big Data for Bio Intelligence, Chongqing University of Posts and Telecommunications, Chongqing, 400065, P. R. China. liyinghong@cqupt.edu.cn.
Zhuohao Tong *Chongqing Key Laboratory of Big Data for Bio Intelligence, Chongqing University of Posts and Telecommunications, Chongqing, 400065, P. R. China.
Yinqi YangChongqing Key Laboratory of Big Data for Bio Intelligence, Chongqing University of Posts and Telecommunications, Chongqing, 400065, P. R. China.
Yu WangChongqing Key Laboratory of Big Data for Bio Intelligence, Chongqing University of Posts and Telecommunications, Chongqing, 400065, P. R. China.
Lu WenChongqing Key Laboratory of Big Data for Bio Intelligence, Chongqing University of Posts and Telecommunications, Chongqing, 400065, P. R. China.
Yuke LiChongqing Key Laboratory of Big Data for Bio Intelligence, Chongqing University of Posts and Telecommunications, Chongqing, 400065, P. R. China.
Mingze BaiChongqing Key Laboratory of Big Data for Bio Intelligence, Chongqing University of Posts and Telecommunications, Chongqing, 400065, P. R. China.
Yongfang XieChongqing Key Laboratory of Big Data for Bio Intelligence, Chongqing University of Posts and Telecommunications, Chongqing, 400065, P. R. China.
Bo LiCollege of Life Sciences, Chongqing Normal University, Chongqing, 401331, P. R. China. libcell@cqnu.edu.cn.
Kunxian ShuChongqing Key Laboratory of Big Data for Bio Intelligence, Chongqing University of Posts and Telecommunications, Chongqing, 400065, P. R. China. shukx@cqupt.edu.cn.

Funding

China Postdoctoral Science Foundation No. 2021MD703942Chongqing Municipal Postdoctoral Science Special Foundation No. 2021XM2016Chongqing Natural Science Foundation No. cstc2021jcyj-msxmX0834Innovation and Entrepreneurship Training Program for College Students in Chongqing No. S202010617010National Natural Science Foundation of China No. 62101087Science and Technology Research Program of the Chongqing Municipal Education Commission No. KJQN202100538Science and Technology Research Program of the Chongqing Municipal Education Commission No.KJQN202100642
6 · The paper itself

Abstract

backgroundLung cancer remains a leading cause of cancer-related mortality, primarily because of the lack of effective diagnostic and therapeutic biomarkers. To address the issue of fragmented biomarker data across numerous publications, we have developed the Lung Cancer Biomarker Database (LCBD, http://lcbd.biomarkerdb.com ).

methodsWe comprehensively reviewed biomarker-related studies up to June 30, 2023, and extracted relevant biomarker information. The identified biomarkers were systematically annotated, including genes, proteins, GO terms, KEGG pathways, biomarker types, molecular types, developmental stages, discovery methods, sources, populations, and sample sizes. The LCBD online platform was developed to integrate lung cancer biomarker data, and provide search, browsing, and data download functions for researchers. To validate the data in the LCBD, we conducted three case studies comparing models with and without LCBD data.

resultsAfter deduplication and summarization, we collected 1,447 unique biomarkers that were systematically annotated. We then developed the LCBD specifically for use in lung cancer diagnosis. The validity of the biomarkers in the LCBD was confirmed using prognostic models, diagnostic models, and immune infiltration models.

conclusionThe LCBD provides a centralized platform for lung cancer biomarkers, facilitating early screening and personalized treatment. This database is poised to become a valuable resource for lung cancer research and therapeutic strategies.

Indexed as

Biomarkers, TumorDatabases, FactualLung NeoplasmsComputational BiologyDatabases, GeneticHumansPrognosisBiomarkers, TumorBiomarker databaseImmune infiltration modelLung cancerPrognostic model

Identifiers

PMID40089661
PMCPMC11909856

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.